Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Placebo-controlled, Double-blind, Randomized Clinical Study to Assess the Safety and Efficacy of Topical Treatment of AR/101 Compared With for up to 28 Days, in Accelerating Granulation Tissue Formation in Chronic Wound Patients

NCT02839226 is registered in ClinicalTrials.gov with Arava Bio Tech Ltd. as lead sponsor.

NCT NCT02839226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02839226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Placebo-controlled, Double-blind, Randomized Clinical Study to Assess the Safety and Efficacy of Topical Treatment of AR/101 Compared With for up to 28 Days, in Accelerating Granulation Tissue Formation in Chronic Wound Patients
Lead sponsor
Arava Bio Tech Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2016
Completion date
December 31, 2017
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

other ulcers wounds and skin problems, wounds